Nurix Therapeutics Inc [NRIX] stock is trading at $11.56, up 0.35%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NRIX shares have gain 12.89% over the last week, with a monthly amount drifted -9.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on March 17, 2025, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $16. Previously, BTIG Research started tracking the stock with Buy rating on December 10, 2024, and set its price target to $35. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $35 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $35 on October 24, 2024. Jefferies initiated its recommendation with a Buy and recommended $41 as its price target on October 11, 2024. In a note dated July 31, 2024, Truist initiated an Buy rating and provided a target price of $36 on this stock.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $8.18 and $29.56 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $11.56 at the most recent close of the market. An investor can expect a potential return of 96.11% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 56.42M for the trailing twelve months, which represents a growth of 11.26%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -4.09%, Pretax Profit Margin comes in at -3.69%, and Net Profit Margin reading is -3.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.47 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.27 points at the first support level, and at 10.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.79, and for the 2nd resistance point, it is at 12.02.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 6.26. In addition, the Quick Ratio stands at 6.26 and the Cash Ratio stands at 0.84. Considering the valuation of this stock, the price to sales ratio is 15.62, the price to book ratio is 1.83.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Mar 03 ’25 when 5825.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on Mar 03 ’25 to buy 5825.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 5760.0 shares on Jan 31 ’25.
